ACADIA Pharmaceuticals (MEX:ACAD) GF Value Rank: 9 (As of Jul. 12, 2026) — 80% Above Median


MEX:ACAD ACADIA Pharmaceuticals Inc MEX:ACAD
74 GF Score
Price MXN460.00
GF Value MXN496.97
Valuation Fairly Valued
! 10 Warning Signs
View Full Analysis

What is ACADIA Pharmaceuticals GF Value Rank?

ACADIA Pharmaceuticals MEX:ACAD 74 GF Value Rank is 9 as of Jul. 12, 2026, which is 80% above its 10-year median of 5.00. GuruFocus rates MEX:ACAD with a GF Score™ of 74/100 and a GF Value™ of MXN496.97 (Fairly Valued). The stock has 10 warning signs investors should review.

ACADIA Pharmaceuticals has the GF Value Rank of 9.

GF Value Rank evaluates the exclusive GuruFocus valuation and performance of a stock, rated on a scale from 1 to 10. It is determined by the price-to-GF-Value (P/GF Value) ratio, a proprietary metric calculated based on historical multiples along with an adjustment factor based on a company's past returns and growth and future estimates of the business' performance.

GuruFocus found that for valuation, we cannot simply give stocks a better GF Value rank simply because they have a lower P/GF Value ratio. Backtesting shows that over the long term, the two worst-performing groups are the most expensive group (with the highest P/GF Value ratio) and the least expensive group (with the lowest P/GF Value ratio).

We can understand why the most expensive group underperforms. We were initially puzzled by the underperformance of the least expensive group, but we realized there is a reason why some stocks are super cheap. If they look too undervalued, it is often because the businesses behind them are poor quality. The market realized this and gave them low valuations. In a way, the market is efficient.

After multiple backtesting analyses, we granted the stocks in third-cheapest percentile the highest GF Value rank, as they have performed the best over a full market cycle. Stock performance is actually not as sensitive to valuation as it is to growth and profitability. On average, the companies in the 20%-50% valuation groups have similar performances. Therefore, we should avoid the most expensive and the least expensive stocks. We can be more tolerant of valuation.

A higher score indicates a stock with a relatively low valuation and substantial potential for outperformance. Conversely, a lower score often reflects stocks that are either highly overvalued or deeply undervalued, both of which tend to underperform.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.


ACADIA Pharmaceuticals GF Value Rank Related Terms


MEX:ACAD vs VKTX, EWTX, DNLI: GF Value Rank Comparison

For the Biotechnology subindustry, ACADIA Pharmaceuticals's GF Value Rank, along with its competitors' market caps and GF Value Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ACADIA Pharmaceuticals GF Value Rank vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ACADIA Pharmaceuticals's GF Value Rank distribution charts can be found below:

* The bar in red indicates where ACADIA Pharmaceuticals's GF Value Rank falls into.


MEX:ACAD
74GF Score
ACADIA Pharmaceuticals Inc MEX:ACAD
GF Value Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about GF Value Rank →
What does a GF Value Rank of 9 mean?
ACADIA Pharmaceuticals (MEX:ACAD) has a GF Value Rank of 9 as of Jul. 12, 2026. GF Value Rank is given based on historical multiples along with past returns, growth and future estimates of the business' performance. View historical data on ACADIA Pharmaceuticals and its competitors. This is 80% above median its historical median of 5.00. Over the past decade, ACADIA Pharmaceuticals' GF Value Rank has ranged from 2.00 to 10.00.
Is ACADIA Pharmaceuticals' GF Value Rank too high?
ACADIA Pharmaceuticals' current GF Value Rank of 9 is 80% above median its 10-year median of 5.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 10.00. Overall, ACADIA Pharmaceuticals has a GF Score™ of 74/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does ACADIA Pharmaceuticals' GF Value Rank compare to VKTX and EWTX?
ACADIA Pharmaceuticals' GF Value Rank of 9 can be compared against companies in the Biotechnology industry. Historically, ACADIA Pharmaceuticals' own GF Value Rank has ranged from 2.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Value Rank for a Biotechnology company?
A good GF Value Rank depends on the Biotechnology industry context. However, GF Value Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Value Rank mean?
A high GF Value Rank can signal that a stock is expensive relative to its fundamentals. GF Value Rank is given based on historical multiples along with past returns, growth and future estimates of the business' performance. View historical data on ACADIA Pharmaceuticals and its competitors. ACADIA Pharmaceuticals's current GF Value Rank is 9, which is 80% above median its own 10-year median of 5.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ACADIA Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, ACADIA Pharmaceuticals (MEX:ACAD) is currently considered Fairly Valued. The stock's GF Value™ is MXN496.97, compared to a current price of MXN460.00 — trading 7.4% below its estimated fair value. The current GF Value Rank is 9, which is 80% above median its 10-year median of 5.00. ACADIA Pharmaceuticals' overall GF Score™ is 74/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Value Rank calculated?
GF Value Rank is calculated from a company's financial statements. For ACADIA Pharmaceuticals (MEX:ACAD), the current GF Value Rank is 9 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ACADIA Pharmaceuticals (MEX:ACAD) Overvalued in 2026?

Based on GuruFocus' analysis, ACADIA Pharmaceuticals stock appears to be undervalued. The current stock price of MXN460.00 is trading 7.4% below its estimated GF Value™ of MXN496.97. GuruFocus considers ACADIA Pharmaceuticals to be Fairly Valued.

Key valuation signals for MEX:ACAD:

  • GF Value Rank: 9 (80% above median its 10-year median of 5.00)
  • GF Value™: MXN496.97 vs. price of MXN460.00 (7.4% below fair value)
  • GF Score™: 74/100 with 10 warning signs

No single metric tells the full story. See the MEX:ACAD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


ACADIA Pharmaceuticals Business Description

Other Exchanges ACAD:USADR6:Germany
Address 12830 El Camino Real, Suite 400, San Diego, CA, USA, 92130
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-211, ACP-711, ACP-2591, etc.
74GF Score

Get the complete analysis for MEX:ACAD

GF Value Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN460.00
Price
MXN496.97
GF Value